126 related articles for article (PubMed ID: 35078201)
1. Trastuzumab Emtansine-Induced Nodular Regenerative Hyperplasia: Is Dose Reduction Enough as a Preventable Measure?
Garrido I; Magalhães A; Lopes J; Macedo G
Dig Dis; 2022; 40(6):787-792. PubMed ID: 35078201
[TBL] [Abstract][Full Text] [Related]
2. Safety of trastuzumab after trastuzumab emtansine-induced nodular regenerative hyperplasia: A case report.
Hassan C; Correal F; Vézina G; Yelle L; Adam JP
J Oncol Pharm Pract; 2020 Oct; 26(7):1780-1784. PubMed ID: 32192389
[TBL] [Abstract][Full Text] [Related]
3. Nodular Regenerative Hyperplasia Induced by Trastuzumab Emtansine: Role of Emtansine?
Lepelley M; Allouchery M; Long J; Boucherle D; Ranchoup Y; Le Marc'Hadour F; Villier C; Sturm N
Ann Hepatol; 2018 Oct; 17(6):1067-1071. PubMed ID: 30600283
[TBL] [Abstract][Full Text] [Related]
4. Sinusoidal obstruction syndrome post-treatment with trastuzumab emtansine (T-DM1) in advanced breast cancer.
Fujii Y; Doi M; Tsukiyama N; Hattori Y; Ohya K; Shiroma N; Morio K; Morioka T; Aikata H; Shinozaki K; Chayama K
Int Cancer Conf J; 2020 Jan; 9(1):18-23. PubMed ID: 31950012
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study.
Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA
Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab-emtansine induced pleural and pericardial effusions.
Lombardi J; Lory P; Martin N; Mayeur D; Combret S; Grandvuillemin A; Boulay C; Schmitt A
J Oncol Pharm Pract; 2021 Dec; 27(8):2041-2044. PubMed ID: 34000917
[TBL] [Abstract][Full Text] [Related]
7. Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity.
Yan H; Endo Y; Shen Y; Rotstein D; Dokmanovic M; Mohan N; Mukhopadhyay P; Gao B; Pacher P; Wu WJ
Mol Cancer Ther; 2016 Mar; 15(3):480-90. PubMed ID: 26712117
[TBL] [Abstract][Full Text] [Related]
8. Ado-trastuzumab emtansine associated spider telangiectasia.
Gursoy P; Acar A; Acikalin T
J Oncol Pharm Pract; 2022 Jun; 28(4):986-988. PubMed ID: 35040682
[TBL] [Abstract][Full Text] [Related]
9. Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G; Huang CS; Mano MS; Loibl S; Mamounas EP; Untch M; Wolmark N; Rastogi P; Schneeweiss A; Redondo A; Fischer HH; Jacot W; Conlin AK; Arce-Salinas C; Wapnir IL; Jackisch C; DiGiovanna MP; Fasching PA; Crown JP; Wülfing P; Shao Z; Rota Caremoli E; Wu H; Lam LH; Tesarowski D; Smitt M; Douthwaite H; Singel SM; Geyer CE;
N Engl J Med; 2019 Feb; 380(7):617-628. PubMed ID: 30516102
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of trastuzumab emtansine (T-DM1) as a single agent or in combination with pertuzumab in HER2-positive breast cancer patients with recurrent or locally advanced metastatic breast cancer.
Lu D; Li C; Riggs M; Polhamus D; French J; Agarwal P; Chen SC; Vadhavkar S; Patre M; Strasak A; Quartino A; Jin JY; Girish S
Cancer Chemother Pharmacol; 2019 Jul; 84(1):175-185. PubMed ID: 31102024
[TBL] [Abstract][Full Text] [Related]
11. Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.
Baron JM; Boster BL; Barnett CM
J Oncol Pharm Pract; 2015 Apr; 21(2):132-42. PubMed ID: 24682654
[TBL] [Abstract][Full Text] [Related]
12. Case series of docetaxel, trastuzumab, and pertuzumab (DTP) as first line anti-HER2 therapy and ado-trastuzumab emtansine (T-DM1) as second line for recurrent or metastatic HER2-positive salivary duct carcinoma.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Driessen CML; van Herpen CML
Oral Oncol; 2022 Feb; 125():105703. PubMed ID: 34995931
[TBL] [Abstract][Full Text] [Related]
13. An integrated multiple-analyte pharmacokinetic model to characterize trastuzumab emtansine (T-DM1) clearance pathways and to evaluate reduced pharmacokinetic sampling in patients with HER2-positive metastatic breast cancer.
Lu D; Joshi A; Wang B; Olsen S; Yi JH; Krop IE; Burris HA; Girish S
Clin Pharmacokinet; 2013 Aug; 52(8):657-72. PubMed ID: 23553425
[TBL] [Abstract][Full Text] [Related]
14. Concomitant Use of Ado-trastuzumab Emtansine and Imatinib in a Patient of CML and Metastatic Breast Cancer.
Karacin C; Bilgetekin I; Basal FB; Oksuzoglu OB
J Coll Physicians Surg Pak; 2022 Nov; 32(11):1501-1502. PubMed ID: 36377026
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and exposure-response of trastuzumab emtansine in advanced breast cancer previously treated with ≥2 HER2-targeted regimens.
Chen SC; Quartino A; Polhamus D; Riggs M; French J; Wang X; Vadhavkar S; Smitt M; Hoersch S; Strasak A; Jin JY; Girish S; Li C
Br J Clin Pharmacol; 2017 Dec; 83(12):2767-2777. PubMed ID: 28733983
[TBL] [Abstract][Full Text] [Related]
16. Impact of obesity on safety outcomes and treatment modifications with ado-trastuzumab emtansine in breast cancer patients.
Lee A; Larck C; Moore DC
J Oncol Pharm Pract; 2022 Jan; 28(1):49-54. PubMed ID: 33356991
[TBL] [Abstract][Full Text] [Related]
17. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
[TBL] [Abstract][Full Text] [Related]
18. Splenic Enlargement and Bone Marrow Hyperplasia in Patients Receiving Trastuzumab-Emtansine for Metastatic Breast Cancer.
Kosmin M; Makris A; Jawad N; Woolf D; Miles D; Padhani AR
Target Oncol; 2017 Apr; 12(2):229-234. PubMed ID: 28110417
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab emtansine for HER2-positive advanced breast cancer.
Verma S; Miles D; Gianni L; Krop IE; Welslau M; Baselga J; Pegram M; Oh DY; Diéras V; Guardino E; Fang L; Lu MW; Olsen S; Blackwell K;
N Engl J Med; 2012 Nov; 367(19):1783-91. PubMed ID: 23020162
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
